Key result
Higher urinary VOC metabolites linked to increased odds of depressive symptoms in CKM syndrome.
Why the study?
Are higher urinary levels of volatile organic compound metabolites associated with increased depressive symptoms in U.S. adults with cardiovascular-kidney-metabolic syndrome stages 0-3?
Observational
Yes
Are higher urinary levels of volatile organic compound metabolites associated with increased depressive symptoms in U.S. adults with cardiovascular-kidney-metabolic syndrome stages 0-3?
Answers are grounded in this paper and cite their sources.
Higher urinary levels of specific volatile organic compound metabolites are associated with increased odds of depressive symptoms in adults with CKM syndrome stages 0-3, potentially mediated by PI3K/AKT-related neuroimmune pathways.
BACKGROUND: Depression is a major global public health burden, and environmental pollutants are increasingly associated with depressive symptoms. Volatile organic compounds (VOCs) are ubiquitous environmental contaminants with known neurotoxic potential; however, their associations with depressive symptoms, particularly in metabolically vulnerable populations such as those with cardiovascular-kidney-metabolic (CKM) syndrome, remain insufficiently characterized. METHODS: We conducted a population-based study of adults with CKM stages 0-3 using data from NHANES 2011-2018, assessing associations between urinary levels of 16 VOC metabolites and PHQ-9-defined depressive symptoms using multivariable logistic regression, dose-response modeling, and mixture analyses. Machine learning identified key exposures, network toxicology revealed shared molecular targets and pathways, single-cell RNA sequencing characterized cell-type-specific expression and functional states, and molecular docking assessed interactions between prioritized mVOCs and protein targets. RESULTS: Higher urinary levels of CYMA, MHBMA3, and HMPMA were significantly associated with increased odds of depressive symptoms after full adjustment, with approximately linear or nonlinear dose-response relationships. Mixture analysis indicated that these metabolites were the main contributors to the joint VOC exposure effect. Network toxicology identified enrichment of depression-related targets in neuronal signaling, synaptic transmission, and immune regulation pathways. Exploratory analysis of public scRNA-seq datasets suggested higher PIK3R1 expression in PBMC CD8 + T cells from depression-related samples and indicated altered immune-related transcriptional programs. Molecular docking suggested plausible binding interactions between the prioritized VOCs and PIK3R1. CONCLUSIONS: Higher urinary VOC metabolite levels were associated with higher odds of PHQ-9-defined depressive symptoms among adults with CKM stages 0-3. In silico multi-omics analyses suggested potential involvement of PI3K/AKT-related neuroimmune pathways.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted an observational in Cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3. Urinary volatile organic compound metabolites (CYMA, MHBMA3, and HMPMA) was evaluated on PHQ-9-defined depressive symptoms. Higher urinary levels of VOC metabolites CYMA, MHBMA3, and HMPMA were significantly associated with increased odds of depressive symptoms among adults with CKM stages 0-3.
Synapse has enriched 10 related papers. Consider them for comparative context: